Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20230317003
TCTR20230317003
Not yet recruiting
Phase 2

Therapeutic efficiency and safety assessment of intradermal platelet rich plasma combined with oral tranexamic acid in patients with facial melasma

WU grant, Walailak university0 sites20 target enrollmentMarch 17, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsFacial melasmaMelasma

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Facial melasma
Sponsor
WU grant, Walailak university
Enrollment
20
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 17, 2023
End Date
February 1, 2024
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
WU grant, Walailak university

Eligibility Criteria

Inclusion Criteria

  • •1\. Age 18\-60 years
  • •2\. Diagnosed with facial melasma by dermatologists

Exclusion Criteria

  • •1\. Not willing to participate to the study
  • •2\. Allergic to lidocaine, prilocaine, tranexamic acid, chlorhexidine or isopropyl alcohol
  • •3\. Allergic to blood components
  • •4\. Currently treated with other modalities of melasma (or within 6 months)
  • •5\. Pregnancy or lactation
  • •6\. History of hematologic disorders
  • •7\. History of neurologic disorders
  • •8\. History of cancer
  • •9\. Hormonal therapy
  • •10\. Smoking/alcohol drinking

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
Evaluation of therapeutic efficacy and safety of artesunate-amodiaquine, artemether-lumefantrine and dihydroartemisinine-piperaquine for the treatment of uncomplicated Plasmodium falciparum in Democratic Republic of CongoMalariaInfection - Studies of infection and infectious agents
ACTRN12616001423404Ministry of Health534
Active, not recruiting
Phase 1
Study of the safety and effectiveness of drug AZD4017 at reducing pressure in the brain, in idiopathic intracranial hypertension.Idiopathic Intracranial HypertensionMedDRA version: 18.0Level: PTClassification code 10004277Term: Benign intracranial hypertensionSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2013-003643-31-GBniversity of Birmingham30
Completed
Phase 2
A study on siddha medicine kumaara veeriya kaantha chenduram for anaemiaHealth Condition 1: D508- Other iron deficiency anemias
CTRI/2019/04/018795Ayothidoss Pandithar hospital30
Not yet recruiting
Phase 2
Evaluation of safety and therapeutic efficacy of siddha drug KANDAAMALAGA ILAKAM in the treatment of Iron deficiency anaemia.Health Condition 1: null- patients complaints with pallor of skin and mucus membrane, fatigue, lassitude,chest discomfort, breathlessness,pica,giddiness,dizziness,angular stomatitis, pungent or bitter taste.
CTRI/2018/05/014111Ayothidoss Pandithar Hospital
Active, not recruiting
Not Applicable
Safety and effectiveness clinical evaluation of injectable medical device Hydragel A1 in the skin quality improvementPatient seeking aesthetic treatment of the facial skin quality such as skin elasticity or firmness and facial skin radianceNot Applicable
ISRCTN10640292ouna Aesthetics40